Benzinga | Feb 23, 2021 08:19AM EST

electroCore Announces Two-Year Extension Of gammaCore Listing In NHS Supply Chain Catalogue

ROCKAWAY, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, announced today that gammaCore will continue to be listed in the NHS Supply Chain catalogue for an additional two years through June 3, 2023. The original listing, which commenced on June 4, 2019, was scheduled to terminate on June 3, 2021.

"We are pleased that this extension will allow NHS trusts and healthcare organizations the option to continuously procure gammaCore Sapphire(tm) (nVNS) through the NHS Supply Chain online catalogue for an additional two years," stated Iain Strickland, Vice President of European Operations at electroCore. "Importantly, inclusion in this catalogue helps ensure gammaCore therapy is broadly accessible to patients across the UK who may benefit from non-invasive vagus nerve stimulation."

The role of the NHS Supply Chain is to help the NHS deliver clinically assured, quality products at the best value to its patients. The inclusion of gammaCore in the catalogue allows hospitals to purchase gammaCore Sapphire(tm) for their primary headache patients, taking into account their own budgetary restrictions. The listing of gammaCore Sapphire(tm) as an e-Direct product marks a key milestone in the Company providing its medical technologies to UK patients, in an easier, cost-effective way.